论文部分内容阅读
目的观察瑞舒伐他汀联合二甲双胍治疗初诊肥胖型2型糖尿病的临床疗效。方法将212例初诊肥胖型2型糖尿病患者随机分为治疗组和对照组各106例。对照组采用盐酸二甲双胍治疗。治疗组在对照组基础上加用瑞舒伐他汀睡前服用。治疗后对比2组临床疗效。结果治疗组总有效率为93.4%高于对照组的20.8%,差异有统计学意义(P<0.01)。结论瑞舒伐他汀联合二甲双胍治疗初诊肥胖型2型糖尿病疗效较好,值得临床推广应用。
Objective To observe the clinical efficacy of rosuvastatin combined with metformin in the treatment of newly diagnosed obese type 2 diabetes mellitus. Methods 212 newly diagnosed obese type 2 diabetic patients were randomly divided into treatment group and control group of 106 cases. The control group was treated with metformin hydrochloride. The treatment group was given rosuvastatin on the basis of the control group before bedtime. After treatment, the clinical efficacy of two groups were compared. Results The total effective rate of the treatment group was 93.4% higher than that of the control group (20.8%), the difference was statistically significant (P <0.01). Conclusion Rosuvastatin combined with metformin in the treatment of newly diagnosed obese type 2 diabetes is effective and worthy of clinical application.